[go: up one dir, main page]

MA49069A - Procédés et compositions pour le traitement d'apnée du sommeil - Google Patents

Procédés et compositions pour le traitement d'apnée du sommeil

Info

Publication number
MA49069A
MA49069A MA049069A MA49069A MA49069A MA 49069 A MA49069 A MA 49069A MA 049069 A MA049069 A MA 049069A MA 49069 A MA49069 A MA 49069A MA 49069 A MA49069 A MA 49069A
Authority
MA
Morocco
Prior art keywords
compositions
treatment
methods
sleep apnea
apnea
Prior art date
Application number
MA049069A
Other languages
English (en)
Inventor
Luigi Taranto-Montemurro
D Andrew Wellman
Original Assignee
Brigham & Womens Hospital Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63918622&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA49069(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Brigham & Womens Hospital Inc filed Critical Brigham & Womens Hospital Inc
Publication of MA49069A publication Critical patent/MA49069A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
MA049069A 2017-04-28 2018-04-26 Procédés et compositions pour le traitement d'apnée du sommeil MA49069A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762491504P 2017-04-28 2017-04-28
US201762558814P 2017-09-14 2017-09-14
PCT/US2018/029518 WO2018200775A1 (fr) 2017-04-28 2018-04-26 Procédés et compositions pour le traitement d'apnée du sommeil

Publications (1)

Publication Number Publication Date
MA49069A true MA49069A (fr) 2020-03-04

Family

ID=63918622

Family Applications (1)

Application Number Title Priority Date Filing Date
MA049069A MA49069A (fr) 2017-04-28 2018-04-26 Procédés et compositions pour le traitement d'apnée du sommeil

Country Status (22)

Country Link
US (4) US11123313B2 (fr)
EP (1) EP3615016A4 (fr)
JP (2) JP7373997B2 (fr)
KR (2) KR102682159B1 (fr)
CN (2) CN119185558A (fr)
AU (2) AU2018260666B2 (fr)
BR (1) BR112019022483A2 (fr)
CA (1) CA3061468A1 (fr)
CO (1) CO2019013180A2 (fr)
CR (1) CR20190546A (fr)
DO (1) DOP2019000274A (fr)
EC (1) ECSP19084058A (fr)
GE (2) GEP20227387B (fr)
MA (1) MA49069A (fr)
MX (2) MX394941B (fr)
MY (1) MY200172A (fr)
NI (1) NI201900110A (fr)
PH (1) PH12019502427A1 (fr)
SG (2) SG11201909973UA (fr)
UA (1) UA127759C2 (fr)
WO (1) WO2018200775A1 (fr)
ZA (1) ZA201907158B (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3615016A4 (fr) * 2017-04-28 2021-02-24 The Brigham and Women's Hospital, Inc. Procédés et compositions pour le traitement d'apnée du sommeil
SG11202007226UA (en) * 2018-01-30 2020-08-28 Apnimed Inc Delaware Methods and compositions for treating sleep apnea
CN108309261B (zh) * 2018-02-11 2020-05-22 西安交通大学 一种猝死预警方法及装置和系统
US20190381056A1 (en) 2018-06-17 2019-12-19 Axsome Therapeutics, Inc. Compositions for delivery of reboxetine
US20200147093A1 (en) 2018-10-15 2020-05-14 Axsome Therapeutics, Inc. Use of esreboxetine to treat nervous system disorders such as fibromyalgia
US11020402B2 (en) 2018-10-15 2021-06-01 Axsome Therapeutics, Inc. Use of reboxetine to treat narcolepsy
JP2022506113A (ja) * 2018-10-31 2022-01-17 アプニメッド，インコーポレイテッド（デラウェア） 睡眠時無呼吸を治療するための方法及び組成物
JP2022519721A (ja) 2019-02-08 2022-03-24 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド 睡眠時無呼吸を治療するための方法および組成物
US20220362221A1 (en) * 2019-11-04 2022-11-17 Apnimed, Inc. (Delaware) Combination pharmacological interventions for multiple mechanisms of obstructive sleep apnea
CN114159568A (zh) * 2020-09-11 2022-03-11 北京原基华毅生物科技有限公司 Sik抑制剂在制备用于预防和/或治疗睡眠障碍的药物中的应用
RU2757470C1 (ru) * 2020-11-19 2021-10-18 Ренат Рашитович Ахмеров Способ лечения храпа с помощью введения тромбоцитарной аутологичной плазмы
WO2022155162A1 (fr) * 2021-01-14 2022-07-21 Apnimed, Inc. (Delaware) Méthodes et compositions pour traiter l'apnée du sommeil
WO2022187420A1 (fr) * 2021-03-04 2022-09-09 Apnimed, Inc. (Delaware) Combinaison de réboxétine et d'un antagoniste du récepteur muscarinique (arm) destinée à être utilisée dans le traitement de l'apnée du sommeil
WO2022221613A1 (fr) * 2021-04-16 2022-10-20 Apnimed, Inc. (Delaware) Combinaison d'un inhibiteur de recaptage de la norépinéphrine et d'un cannabinoïde pour une utilisation dans le traitement de l'apnée du sommeil
MX2023014709A (es) * 2021-06-17 2024-01-15 Apnimed Inc Delaware Inhibidores de la recaptacion de norepinefrina para tratamiento de la apnea del sue?o.
CN117956959A (zh) * 2021-08-31 2024-04-30 爱普宁公司(特拉华) 用于治疗睡眠呼吸暂停的方法和组合物
EP4452245A1 (fr) 2021-12-22 2024-10-30 Bayer Aktiengesellschaft Combinaison associant des antagonistes de l'adrénorécepteur alpha 2 du sous-type c (alpha-2c) et un antagoniste du récepteur muscarinique pour le traitement de l'apnée du sommeil
KR20240127384A (ko) * 2021-12-22 2024-08-22 바이엘 악티엔게젤샤프트 수면 무호흡의 치료를 위한 task1/3 채널 차단제와 노르에피네프린 재흡수 억제제의 조합물
TW202342033A (zh) 2021-12-22 2023-11-01 德商拜耳廠股份有限公司 用於治療睡眠呼吸中止之α２－腎上腺素受體亞型Ｃ（α－２Ｃ）拮抗劑與正腎上腺素再吸收抑制劑之組合
EP4522149A1 (fr) * 2022-05-13 2025-03-19 Apnimed, Inc. (Delaware) Méthodes et compositions pour le traitement de l'apnée du sommeil

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1191930A2 (fr) 1999-05-20 2002-04-03 Sepracor Inc. Procedes de traitement de l'asthme a l'aide de s-oxybutynine
NZ520975A (en) * 2000-02-24 2004-03-26 Upjohn Co New drug combinations containing a norepinephrine reuptake inhibitor and an antimuscarinic agent for treating nervous system disorders
US20060039866A1 (en) * 2004-08-20 2006-02-23 Cypress Bioscience, Inc. Method for treating sleep-related breathing disorders
AU2005319367B2 (en) * 2004-12-20 2012-05-24 Collegium Pharmaceutical, Inc. Pharmaceutical compositions for sleep disorders
US8753327B2 (en) * 2011-01-28 2014-06-17 Pfantastic Medical Research Institute, Llc Methods for treating obstructive sleep apnea
EP3615016A4 (fr) * 2017-04-28 2021-02-24 The Brigham and Women's Hospital, Inc. Procédés et compositions pour le traitement d'apnée du sommeil
SG11202007226UA (en) * 2018-01-30 2020-08-28 Apnimed Inc Delaware Methods and compositions for treating sleep apnea

Also Published As

Publication number Publication date
DOP2019000274A (es) 2019-12-30
US20200054583A1 (en) 2020-02-20
SG11201909973UA (en) 2019-11-28
CR20190546A (es) 2020-04-08
CN110799181A (zh) 2020-02-14
GEP20227387B (en) 2022-06-10
EP3615016A4 (fr) 2021-02-24
MX2022010349A (es) 2022-09-19
MX394941B (es) 2025-03-24
BR112019022483A2 (pt) 2020-05-12
KR20190140019A (ko) 2019-12-18
NZ758564A (en) 2023-12-22
KR20240042261A (ko) 2024-04-01
ZA201907158B (en) 2021-09-29
SG10202111623TA (en) 2021-12-30
MX2019012729A (es) 2019-12-19
US20240189261A1 (en) 2024-06-13
JP7373997B2 (ja) 2023-11-06
ECSP19084058A (es) 2020-01-31
PH12019502427A1 (en) 2020-10-05
GEP20247617B (en) 2024-04-25
AU2018260666B2 (en) 2022-07-21
UA127759C2 (uk) 2023-12-27
EP3615016A1 (fr) 2020-03-04
AU2022241471A1 (en) 2022-10-27
US20240261239A1 (en) 2024-08-08
WO2018200775A1 (fr) 2018-11-01
KR102682159B1 (ko) 2024-07-08
MY200172A (en) 2023-12-12
US11123313B2 (en) 2021-09-21
NI201900110A (es) 2020-03-18
CN119185558A (zh) 2024-12-27
CA3061468A1 (fr) 2018-11-01
CO2019013180A2 (es) 2020-02-07
JP2023139000A (ja) 2023-10-03
AU2018260666A1 (en) 2019-11-14
JP2020517719A (ja) 2020-06-18
US20210401777A1 (en) 2021-12-30

Similar Documents

Publication Publication Date Title
MA49069A (fr) Procédés et compositions pour le traitement d'apnée du sommeil
EP3947715A4 (fr) Procédés et compositions pour le traitement du cancer
MA50849A (fr) Substances et procédés pour le traitement d'hémoglobinopathies
MA52861A (fr) Méthodes et compositions pour le traitement de l'apnée du sommeil
MA51306A (fr) Compositions et procédés améliorés pour le traitement du déficit en ornithine transcarbamylase
MA45798A (fr) Compositions et procédés d'inhibition de masp-3 pour le traitement de maladies et troubles divers
MA42819A (fr) Procédés pour le traitement d'infections virales à arenaviridae et coronaviridae
MA51796A (fr) Procédés et compositions pour l'administration de protéines thérapeutiques
EP3496666A4 (fr) Dispositifs et procédés pour le traitement d'une insuffisance valvulaire
MA54609A (fr) Inhibiteurs aza-hétérobicycliques de mat2a et procédés d'utilisation pour le traitement du cancer
EP3448421A4 (fr) Procédés et compositions pour la prévention et le traitement d'adhérences chirurgicales
MA43283A (fr) Procédés et compositions pour le traitement du cancer
MA54608A (fr) Inhibiteurs aza-hétérobicycliques de mat2a et procédés d'utilisation pour le traitement du cancer
EP3341391A4 (fr) Compositions et procédés pour le traitement de la douleur
EP3390642A4 (fr) Compositions et procédés pour le traitement de rétinite pigmentaire 18 et de rétinite pigmentaire 13
EP3866736A4 (fr) Méthodes et dispositifs pour le traitement de l'apnée du sommeil
EP3180022A4 (fr) Cassette d'expression améliorée pour le conditionnement et l'expression de variantes du facteur viii pour le traitement des troubles de l'hémostase
EP3049104A4 (fr) Compositions de vaccins, adjuvants et procédés pour le traitement d'infections urinaires
EP2983619A4 (fr) Logiciel d'orientation et de planification chirurgicales pour le traitement de l'astigmatisme
MA53873A (fr) Compositions et procédés pour le traitement de la presbytie
MA43170A (fr) Association d'un inhibiteur de bcl-2 et d'un inhibiteur de mek pour le traitement du cancer
SG11202011296VA (en) Compositions and methods for the treatment of parkinson's disease
MA51056A (fr) Compositions et méthodes pour le traitement d'affections métaboliques
EP3781214A4 (fr) Compositions et procédés de traitement de l'amyotrophie spinale
MA49576A (fr) Compositions et méthodes pour le traitement d'infections fongiques